New research evaluates a number of new blood tests (called biomarkers) in people who have had AKI, aiming to improve the ability to assess risk new or progressive kidney disease.
Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumour Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C and eGFR.
This combination discriminated between those with and without worsening CKD after three years, and was particularly good at identifying those at lowest risk for progressive kidney disease.
These findings are published in the American Journal of Kidney Diseases suggest that biomarkers after AKI may be useful in identifying patients with very low risk of subsequent kidney dysfunction and a lower need for medical follow-up.
Source: Medindia
